Janssen Nov 7, 2022 Automation Offers No Easy Answers to CAR T-Cell Supply Shortfalls Premium Oct 12, 2022 Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies Premium Sep 22, 2022 Persephone Biosciences Enrolls First Patient in Study of Microbiome Effect on Cancer Drug Response Sep 1, 2022 Multiple Myeloma Researchers Chip Away at Why Some Patients Relapse Quickly After CAR T-Cell Therapy Premium Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Jul 26, 2022 Legend Biotech Aims to Raise $250M via Public Offering of American Depositary Shares Jul 11, 2022 Legend Biotech Shutters Trial of CD4-Directed CAR T-Cell Therapy for T-Cell Lymphoma Jun 16, 2022 Janssen Hoping to Bring Tissue-Agnostic Data on Balversa to Regulators Next Year Premium Jun 15, 2022 Paige, Janssen Partner on Bladder Cancer Dx Jun 9, 2022 Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study May 26, 2022 European Commission Gives Conditional Approval to Carvykti for Multiple Myeloma May 19, 2022 UPenn Researchers Find Low Uptake of Janssen's Balversa in Eligible Bladder Cancer Patients Premium May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials Apr 28, 2022 Janssen Seeking European Union Approval for Zejula in HRR-Positive Prostate Cancer Apr 27, 2022 Illumina, Janssen Biotech Form Strategic Partnership to Develop Precision Medicines Apr 21, 2022 Legend Biotech Nets $50M Milestone Payment From Janssen for Carvykti Mar 30, 2022 ConcertAI Nets $150M Investment to Advance Software Solutions for Cancer Drug Trials Mar 25, 2022 EMA's CHMP Issues Positive Recommendations for Novartis' Kymriah, Janssen's Carvykti Mar 11, 2022 Tyra Biosciences, xCures Launch Real-World Biomarker Study in FGFR-Mutated Bladder Cancer Mar 4, 2022 Multiple Myeloma Patients Get Second CAR T-Cell Therapy Amid Growing Demand Premium Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
